Intuitive Surgical Inc. (ISRG) Buy, Sell or…

Home

Daily Stock Opinions and Ratings

Intuitive Surgical Inc. (ISRG)

405.61

-5.94 (1.44%)

as of Jul 10, 2026, 6:52:02 pm Market Open.

128 watching

Investor Insights

Jul 10, 2026, 12:00 am

This summary was created by AI, based on 7 opinions in the last 12 months.

Intuitive Surgical Inc. (ISRG-Q) is facing a challenging environment characterized by an overall decline in the med tech sector, although there remains potential for long-term growth in robotic-assisted surgeries. While some experts express concern over recent earnings and forecasts from their Da Vinci business, others note the company's innovation in robotics and believe that the opportunities in this field will continue to expand. Analysts are divided; some are waiting for a more attractive entry point, while others observe that current pricing appears attractive despite the recent decline in stock value. The upcoming earnings report is anticipated with caution, as previous surprises may not be sustainable due to growing competition in the market. Overall, the company remains a subject of interest for long-term investors, especially if it can navigate its current challenges effectively.

Consensus

Cautious

Valuation

Fair Value

Similar

PNUX

BUY

JNJ JNJ is trying to respond to the rise of robotic surgery by Intuitive Surgical, which he prefers. This take time and research for JNJ, which means Intuitive will still be ahead of JNJ.

BUY

Allan Tong’s Discover Picks Both Jamie Murray and Bruce Murray (unrelated) see strong long-term growth ahead for the company as more surgeons adapt robotic devices. ISRG's market share is currently only 4%, but Bruce Murray expects the company to grow 50% next year and 20% after that. However, investors have already caught onto this stock and ISRG stock has almost doubled from the March 23 bottom; it has passed its $655 price target and is flirting with $700. Read BDX, BSX, ISRG and Stryker Stock: Top 4 Medical Supply Stocks for our full analysis.

TOP PICK

The leader in robotic surgery. They have only a 3-5% market share, but will grow as doctors grow more comfortable with robotic surgery. The PE is high, but the growth rate will catch up. He sees 50% growth next year and 20% after. This is a high-growth stock. (Analysts’ price target is $655.19)

PAST TOP PICK

(A Top Pick Aug 19/19, Up 15%) They lead in robotic-assisted surgery, though ISRG has only 4% market penetration. They generate tons of cash with lots of recurring revenue. As more surgeries go robotic in the next 20 years, ISRG will lead the way. Buy and put this away for 20 years.

TOP PICK

The maker of surgical robots. They are the leader in the sector and there is no real competition. With only 5% of surgeries being done robotically there is enormous growth ahead. Yield 0% (Analysts’ price target is $546.67)

TOP PICK

The leader in robotic surgery. They sold about 900 units. He thinks they will continue to grow world-wide. (Analysts’ price target is $612.34)

TOP PICK

It is the largest company that you have never heard of. Their business is robots for surgery. It has been under a bit of pressure from a competitor but that competitor only has 4% penetration globally. (Analysts’ price target is $572.35)

COMMENT

Medical robotics? He does not know TMD-T well. He plays the space through and ETF of BOTZ-Q. He prefers ISRG-Q, if you wanted an individual holding.

COMMENT

Own it through an ETF called BOTZ. That is the way he likes to play into the robotics / machine learning space.

TOP PICK

A disruptor in medtech. ISRG builds robotic-assisted surgical devices that are sold to hospitals. Enjoys 85% recurring revenues. Growing steadily for 20 years with good intenational exposure. Their commerical shows a robot sewing the skin on a grape. Stock rose 8% today alone. Again demographics are another tailwind. (Also look at the IHI ETF in the medtech sector.) (Analysts' price target $460.80)

DON'T BUY

Have the robotic methodology for surgical procedures, which has been very successful but it is priced in. Great company. Trading at 35X earnings which is too expensive.

DON'T BUY

Surgical tool for surgeons to use like a robot. He is worried about it getting well ahead of itself. If anything goes wrong there is a lot of air under that stock price.

DON'T BUY

A high-growth story but too expensive for him now. High beta of 1.3.

Showing 46 to 58 of 58 entries

Most Recent Experts

Darren Sissons

Campbell Lee & Ross

Stan Wong

Private Wealth Management, ScotiaMcleod

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rebecca Teltscher

Newhaven Asset Management

Ernest Wong, Head of Research, Baskin Wealth Management

Baskin Wealth Management

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Intuitive Surgical Inc. (ISRG)